www.fdanews.com/articles/184097-celgene-drops-crohns-disease-drug
Celgene abandoned development of its Crohn’s disease drug Revolve (mongersen) after disappointing results from a Phase III clinical trial.
The drug failed to pass muster in an interim futility analysis, the company said.
Celgene said it will continue development of other drugs for Crohn’s.